CoChat

Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment

Open access

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Abstract

There are fewer than normal glucose transporters at the blood-brain barrier (BBB) in Alzheimer’s disease (AD). When reduced expression of transporters aggravates the symptoms of AD, the transporters become a potential target of therapy. The incretin hormone GLP-1 prevents the decline of cerebral metabolic rate for glucose (CMR glc) in AD, and GLP-1 may serve to raise transporter numbers. We hypothesized that the GLP-1 analog liraglutide would prevent the decline of CMR glc in AD by raising blood-brain glucose transfer, depending on the duration of disease. We randomized 38 patients with AD to treatment with liraglutide (n = 18) or placebo (n = 20) for 6 months, and determined the blood-brain glucose transfer capacity (Tmax) in the two groups and a healthy age matched control group (n = 6). In both AD groups at baseline, Tmax estimates correlated inversely with the duration of AD, as did the estimates of CMR glc that in turn were positively correlated with cognition. The GLP-1 analog treatment, compared to placebo, highly significantly raised the Tmax estimates of cerebral cortex from 0.72 to 1.1 umol/g/min, equal to Tmax estimates in healthy volunteers. The result is consistent with the claim that GLP-1 analog treatment restores glucose transport at the BBB.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-017-17718-y

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Estimates of T max of two groups before and after liraglutide and placebo treatment. Ordinate T max estimates. GLP-1 analog treatment very significantly (P < 0.0001) raised the average T max estimate in cerebral cortex as a whole. The resulting value of T max significantly exceeded the value reached by placebo treatment.
Figure 1 Estimates of T max of two groups before and after liraglutide and placebo treatment. Ordinate T max estimates. GLP-1 analog treatment very significantly (P < 0.0001) raised the average T max estimate in cerebral cortex as a whole. The resulting value of T max significantly exceeded the value reached by placebo treatment.CC BY · PubMed Central
Figure 2 Relationship between duration of AD and CMRglc (A), total cognitive score and CMRglc (B), duration of AD and Tmax, (C), total cognitive score and GUF (D), Tmax and CMRglc (E), and total cognitive score and net clearance of [18F]FDG. The points representing the averages of the healthy control group were not included in the analysis.
Figure 2 Relationship between duration of AD and CMRglc (A), total cognitive score and CMRglc (B), duration of AD and Tmax, (C), total cognitive score and GUF (D), Tmax and CMRglc (E), and total cognitive score and net clearance of [18F]FDG. The points representing the averages of the healthy control group were not included in the analysis.CC BY · PubMed Central
Figure 3 The GLP-1 analog treatment appeared to reduce the effects of disease duration. The results are consistent with the claims (1) that the maximum blood-brain transfer capacity declines with duration of Alzheimer’s disease, and (2) that GLP-1 analog treatment raises the GLUT1 activity in the barrier as a potential future target for treatment of the neurovascular dysfunction in Alzheimer’s disease. Estimates of K t averaged 9.3 mM (± 0.28 RSDR, robust standard deviation of residuals) in the placebo treated group at baseline, 10.1 mM (± 0.19 RSDR) at six months, and 5.9 mM (± 0.18 RSDR) in the liraglutide group at baseline, and 11.1 mM (± 0.25 RSDR) at six months of treatment. The points representing the averages of the healthy control group were not included in the analysis.
Figure 3 The GLP-1 analog treatment appeared to reduce the effects of disease duration. The results are consistent with the claims (1) that the maximum blood-brain transfer capacity declines with duration of Alzheimer’s disease, and (2) that GLP-1 analog treatment raises the GLUT1 activity in the barrier as a potential future target for treatment of the neurovascular dysfunction in Alzheimer’s disease. Estimates of K t averaged 9.3 mM (± 0.28 RSDR, robust standard deviation of residuals) in the placebo treated group at baseline, 10.1 mM (± 0.19 RSDR) at six months, and 5.9 mM (± 0.18 RSDR) in the liraglutide group at baseline, and 11.1 mM (± 0.25 RSDR) at six months of treatment. The points representing the averages of the healthy control group were not included in the analysis.CC BY · PubMed Central
Figure 4 Maximum clearance as function of disease duration of all baseline and placebo treatment groups, and separately for liraglutide group treated for 6 months. Abscissa: Duration (months). Ordinate: Maximum clearance calculated as average of Tmax/Kt ratios for the four groups. Curve represents best fit of exponential growth equation Y = Yo + A exp(−k(X − Xo)) with R2 = 0.4 and parameters + standard errors of Yo = 9.28 + 0.08 ml/hg/min, A = 0.12 + 0.49 ml/hg/min, and k = 0.23 + 0.27 min−1, with Xo fixed at 16.4 months, the average duration of the placebo group members at baseline. The points representing the averages of the healthy control group were not included in the analysis.
Figure 4 Maximum clearance as function of disease duration of all baseline and placebo treatment groups, and separately for liraglutide group treated for 6 months. Abscissa: Duration (months). Ordinate: Maximum clearance calculated as average of Tmax/Kt ratios for the four groups. Curve represents best fit of exponential growth equation Y = Yo + A exp(−k(X − Xo)) with R2 = 0.4 and parameters + standard errors of Yo = 9.28 + 0.08 ml/hg/min, A = 0.12 + 0.49 ml/hg/min, and k = 0.23 + 0.27 min−1, with Xo fixed at 16.4 months, the average duration of the placebo group members at baseline. The points representing the averages of the healthy control group were not included in the analysis.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Cited by

See all 169

Metadata

Authors
Gejl, M., Brock, B., Egefjord, L., Vang, K., Rungby, J., & Gjedde, A.
Affiliations
  • Aarhus University (DK)
  • Aarhus University Hospital (DK)
  • University of Copenhagen (DK)
Corresponding author
Gejl, Michael
Venue
Scientific Reports
Published
2017-12-13
Volume
7
Issue
1
Pages
17490-17490
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2773040321
Cited by
163
References
66
Citations by year
2026: 20 · 2025: 28 · 2024: 19 · 2023: 14 · 2022: 19 · 2021: 21 · 2020: 24 · 2019: 13 · 2018: 4 · 2017: 1
FWCI
8.43
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Aarhus Universitet
  • Aarhus Universitetshospital
  • Novo Nordisk
  • Region Midtjylland
  • Health Research Fund of Central Denmark Region
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, blood-brain barrier, glucose transport, liraglutide, GLP-1 analogues, cerebral metabolic rate of glucose, glucose transporters, disease duration, cognitive function, cerebral cortex
MeSH terms
Liraglutide, Aged, Alzheimer Disease, Blood-Brain Barrier, Cognition, Double-Blind Method, Glucose, Humans, Hypoglycemic Agents, Middle Aged, Treatment Outcome, Fluorodeoxyglucose F18, Positron-Emission Tomography, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment. https://app.cochat.ai/papers/10.1038/s41598-017-17718-y
The paper
Gejl, M., Brock, B., Egefjord, L., Vang, K., Rungby, J., & Gjedde, A. (2017). Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment. Scientific Reports. https://doi.org/10.1038/s41598-017-17718-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.